Federal Register / Vol. 71, No. 172 / Wednesday, September 6, 2006 / Notices 52551 

can help diagnose or follow up on the 

progress of a variety of diseases, 

including Huntington’s Disease, 

olivopontocerebellar atrophy, epilepsy, 

schizophrenia, as well as hepatitis, 

cirrhosis, cholangitis, Gilbert’s diseases, 

muscular dystrophy, leukemia, kidney 

inflammation, cardiac infarction, or the 

presence of a tumor. Thus, tissue AST 

activity may become a novel marker of 

brain disorders which has been 

inaccessible using current clinical 

technologies. 

Applications and Market: Diagnosis 

and monitoring disease status in a 

variety of diseases, including 

Huntington’s Disease, 

olivopontocerebellar atrophy, epilepsy, 

schizophrenia, as well as hepatitis, 

cirrhosis, cholangitis, Gilbert’s diseases, 

muscular dystrophy, leukemia, kidney 

inflammation, cardiac infarction, or the 

presence of a tumor. The diagnostic 

market is a multi-billion dollar market, 

with a need for more efficient noninvasive techniques, markers and new 

methods of diagnosis. 

Patent Status: U.S. Patent Application 

No. 11/356,214 filed 21 Feb 2006 (HHS 

Reference No. E–231–2005/0–US–02). 

Inventors: Dr. Jun Shen (NIMH). 

Publication: J Shen. In vivo carbon-13 

magnetization transfer effect: detection 

of aspartate aminotransferase reaction. 

Magn Reson Med. 2005 Dec; 54(6):1321–

1326. 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Chekesha 

Clingman, Ph.D.; 301/435–5018; 

clingman@mail.nih.gov. 

Dated: August 29, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 06–7439 Filed 9–5–06; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Alternative Medicine; Amended Notice 

of Meeting 

Notice is hereby given of a change in 

the meeting of the National Advisory 

Council for Complementary and 

Alternative Medicine, September 8, 

2006, 9 a.m. to September 8, 2006, 4 

p.m., National Institutes of Health, 

Neuroscience Building, 6001 Executive 

Boulevard, Rooms C & D, Rockville, MD 

20852, which was published in the 

Federal Register on July 28, 2006, 71 FR 

42860. 

This meeting is being amended due to 

the start time change for the Open 

session from 2 p.m. to 1:30 p.m. The 

meeting is partially Closed to the public. 

Dated: August 28, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–7436 Filed 9–5–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

NIMH Eating Disorders Grant Application 

Review. 

Date: September 29, 2006. 

Time: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852, (Telephone 

Conference Call). 

Contact Person: Bettina D. Osborn, Ph.D., 

Scientific Review Administrator, Division of 

Extramural Activities, National Institute of 

Mental Health, National Institutes of Health, 

6001 Executive Blvd., Room 6154, MSC 9609, 

Rockville, MD 20852–9609, 301–443–1178, 

acunab@mail.nih.gov. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

Mental Health Centers for Intervention 

Development and Applied Research (CIDAR). 

Date: October 12–13, 2006. 

Time: 9 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Park Hotel, 8400 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: A. Roger Little, Ph.D., 

Scientific Review Administrator, Division of 

Extramural Activities, National Institute of 

Mental Health, National Institutes of Health, 

6001 Executive Blvd., Room 6157, MSC 9609, 

Rockville, MD 20852–9609, 301–402–5844, 

alittle@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.242, Mental Health Research 

Grants; 93.281, Scientist Development 

Award, Scientist Development Award for 

Clinicians, and Research Scientist Award; 

93.282, Mental Health National Research 

Service Awards for Research Training, 

National Institutes of Health, HHS) 

Dated: August 28, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–7434 Filed 9–5–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institutes of Diabetes and 

Digestive and Kidney Diseases; 

Amended Notice of Meeting 

Notice is hereby given of changes in 

the meeting of the National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council, September 20, 2006, 8:30 a.m. 

to September 21, 2006, 12 p.m., 

National Institutes of Health, Building 

31, 31 Center Drive, Bethesda, MD 

20892, which was published in the 

Federal Register on August 18, 2006, 71 

FR 47820–47821. 

Name of Committee: National Diabetes and 

Digestive and Kidney Diseases Advisory 

Council. 

Date: September 20–21, 2006. 

Open: September 20, 2006, 8:30 a.m. to 12 

p.m. 

Agenda: To present the Director’s Report 

and other scientific presentations. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 10, Bethesda, MD 20892. 

Open: September 20, 2006, 4 p.m. to 5 p.m. 

Agenda: Report from the NIH Director. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 10, Bethesda, MD 20892. 

Closed: September 21, 2006, 9:45 a.m. to 

10:15 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 10, Bethesda, MD 20892. 

Open: September 21, 2006, 10:15 a.m. to 12 

p.m. 

Agenda: Continuation of the Director’s 

Report and other scientific presentations. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 10, Bethesda, MD 20892. 

Contact Person: Brent B. Stanfield, Ph.D., 

Director, Division of Extramural Activities, 

National Institutes of Diabetes and Digestive 

and Kidney Diseases, 6707 Democracy Blvd., 


rwilkins on PROD1PC63 with NOTICES